CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsHigh earnings quality
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.31%Below 5Y avg (0.69%)
Annual Rate
CNY 0.03Paid annual
Payout Ratio
0.0%Sustainable
Last Ex-Dividend
May 27, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.63BCNY688.19M · vs all stocks (USD)
Revenue (TTM)
402.62MCNY59.80M · vs all stocks (USD)
Profit Margin
-5.15%Beta
0.2370xvs all stocks
52-Week Change
-32.21%vs all stocks
Market Capitalization
4.63BCNY688.19M · vs all stocks (USD)
Enterprise Value
3.28BCNY487.77M · vs all stocks (USD)
Price to Sales (TTM)
11.84xPrice to Book (MRQ)
1.41xEnterprise to Revenue
8.16xEnterprise to EBITDA
85.50xGross Margin
68.11%Profit Margin
-5.15%Operating Margin
10.54%Return on Assets (TTM)
-0.15%Return on Equity (TTM)
-0.80%Revenue (TTM)
402.62MCNY59.80M · vs all stocks (USD)
Revenue per Share (TTM)
0.8290CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-2.30%Gross Profit (TTM)
261.15MCNY38.79M · vs all stocks (USD)
EBITDA (TTM)
68.19MCNY10.13M · vs all stocks (USD)
Net Income (TTM)
-20.74MCNY-3.08M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-88.30%Operating Cash Flow (TTM)
27.35MCNY4.06M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-62.09MCNY-9.22M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0300CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.31%vs all stocks
5-Year Average Dividend Yield
0.69%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
21.47MCNYFY2025 · Dec 31, 2025Revenue
404.72MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
141.19MCNYFY2025 · Dec 31, 2025Gross Profit
263.53MCNYFY2025 · Dec 31, 2025Operating Income
-8.87MCNY-1.32M · vs all stocks (USD)
Pre-tax Income
12.30MCNYFY2025 · Dec 31, 2025Income Tax Expense
4.51MCNYFY2025 · Dec 31, 2025Net Income
7.79MCNYFY2025 · Dec 31, 2025EBIT
12.76MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
68.19MCNYFY2025 · Dec 31, 2025Research & Development
69.51MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
152.34MCNYFY2025 · Dec 31, 2025Other Operating Expenses
9.29MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.01MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
454.54KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0300CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0300CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
485.70MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
485.70MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
7.79MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
6.78MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
3.45MCNYFY2025 · Dec 31, 2025Free Cash Flow
-96.66MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
75.82MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
7.79MCNYFY2025 · Dec 31, 2025Other Non-cash Items
100.92KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-12.40MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
7.96MCNYFY2025 · Dec 31, 2025Capital Expenditures
-100.10MCNYFY2025 · Dec 31, 2025Sale of Investments
91.45MCNYFY2025 · Dec 31, 2025Other Investing Activity
-37.07MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-45.73MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
19.99MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-250.89KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
19.74MCNYFY2025 · Dec 31, 2025Shares Outstanding
481.67MSharesUpdated Aug 19, 2026Float Shares
210.92MSharesUpdated Aug 19, 2026% Held by Insiders
57.18%vs all stocks
% Held by Institutions
0.48%vs all stocks
Total Cash (MRQ)
1.62BCNY240.74M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.37CNYUpdated Aug 19, 2026Total Debt (MRQ)
19.68MCNY2.92M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0058xCurrent Ratio (MRQ)
20.09xBook Value per Share (MRQ)
7.01CNYUpdated Aug 19, 2026Total Assets
3.57BCNY529.98M · vs all stocks (USD)
Total Current Assets
1.69BCNYFY2025 · Dec 31, 2025Total Liabilities
175.95MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.88BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
83.66MCNYFY2025 · Dec 31, 2025Total Current Liabilities
92.30MCNYFY2025 · Dec 31, 2025Cash
61.58MCNYFY2025 · Dec 31, 2025Cash Equivalents
26.56MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
88.13MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.47BCNYFY2025 · Dec 31, 2025Accounts Receivable
42.40MCNYFY2025 · Dec 31, 2025Inventory
68.85MCNYFY2025 · Dec 31, 2025Accounts Payable
22.63MCNYFY2025 · Dec 31, 2025Short-term Debt
19.86MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.03MCNYFY2025 · Dec 31, 2025Common Stock (Book)
481.67MCNYFY2025 · Dec 31, 2025Retained Earnings
1.80BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.39BCNY503.85M · vs all stocks (USD)
52-Week Low
7.77CNYUpdated Aug 19, 202652-Week High
14.60CNYUpdated Aug 19, 202652-Week Change
-32.21%vs all stocks
Beta
0.2370xvs all stocks
50-Day MA
9.23CNYUpdated Aug 19, 2026200-Day MA
10.59CNYUpdated Aug 19, 2026Avg 10-Day Volume
10.35MSharesUpdated Aug 19, 2026Avg 30-Day Volume
12.61MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-0.0400CNYUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.68Profit Margin: -0.05
Financial Health
High earnings qualityNotable
Earnings Quality Score: 0.64
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Knight Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Vishee Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
BridgeBio Oncology Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Keyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hangzhou Minsheng Healthcare Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ars Pharmaceuticals Inc
Tier 1ProductionApproval-Gated PipelineRule
Hunan Fangsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Xiangxue Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai ShenQi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Revenio Group Oyj
Tier 1ProductionApproval-Gated PipelineRule